Microbot Medical's LIBERTY System Study Published in Peer-Reviewed Journal, Bolstering Commercialization
MBOT sits 88% above its 52-week low of $1.35.
Summary
Microbot Medical announced the publication of its ACCESS PVI Pivotal Study in a leading peer-reviewed journal, providing significant clinical validation for its FDA-cleared LIBERTY Endovascular Robotic System ahead of its full market release.
Key Events · Product Development and Regulatory · MBOT
-
Pivotal Study Published
Microbot Medical announced the publication of its ACCESS PVI Pivotal Study in the Journal of Vascular and Interventional Radiology (JVIR), a leading peer-reviewed medical journal.
-
Clinical Validation
The publication provides independent, evidence-based validation of the LIBERTY Endovascular Robotic System, which is critical for medical device adoption and credibility.
-
Supports Commercialization
This scientific endorsement follows the system's FDA clearance in September 2025 and precedes its planned full market release in April 2026, strengthening its market position.
Analysis · MBOT · Industrial Applications And Services
The publication of the ACCESS PVI Pivotal Study in a premier peer-reviewed journal provides significant clinical validation for Microbot Medical's LIBERTY Endovascular Robotic System. This milestone, following FDA clearance in September 2025, is crucial for driving broader commercial adoption as the company prepares for a full market release in April 2026. Peer-reviewed data is essential for building trust and acceptance within the medical community, potentially accelerating sales and market penetration.
At the time of this filing, MBOT was trading at $2.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $169.2M. The 52-week trading range was $1.35 to $4.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.